Table 3.
Main results for meta-analysis between p21 and clinicopathological features in esophageal cancer.
| Clinical parameters | OR [95% CI] | P | z | I 2 | P | Begg's test |
|---|---|---|---|---|---|---|
| Tissue | 2.210 [0.811-6.022] | 0.121 | 1.550 | 90.9% | P < 0.05 | 0.373 |
| Age | 0.969 [0.716-1.312] | 0.840 | 0.210 | 81.8% | P < 0.05 | 0.732 |
| Gender | 0.758 [0.566-1.015] | 0.063 | 1.860 | 85.4% | P < 0.05 | 0.484 |
| Differentiation | 2.153 [1.455-3.184] | P < 0.05 | 3.840 | 41.3% | 0.023 | 0.185 |
| Clinical stage | 1.616 [1.068-2.446] | 0.023 | 0.002 | 53.4% | 0.002 | 0.096 |
| Tumor stage | 0.885 [0.541-1.448] | 0.627 | 0.490 | 93.7% | P < 0.05 | 0.089 |
| Lymph node | 1.691 [1.165-2.455] | 0.006 | 2.760 | 57.7% | P < 0.05 | 1.000 |
| Metastasis | 0.637 [0.356-1.140] | 0.129 | 1.520 | 76.7% | P < 0.05 | 0.296 |
| Grading | 3.399 [2.278-5.071] | P < 0.05 | 5.990 | 31.0% | 0.170 | 0.532 |
| Invasion | 1.939 [1.328-2.830] | 0.001 | 3.430 | 58.9% | P < 0.05 | 0.788 |
| Tumor size | 1.005 [0.602-1.675] | 0.986 | 0.020 | 36.0% | 0.181 | 0.806 |
| Tumor location | 0.971 [0.553-1.706] | 0.918 | 0.100 | 51.8% | 0.034 | 0.917 |
| P53 | 1.700 [0.918-3.148] | 0.092 | 1.690 | 63.6% | 0.003 | 0.210 |
| AI (apoptosis index) | 0.131 [0.064-0.269] | P < 0.05 | 5.550 | 65.6% | P < 0.05 | 1.000 |
| Chemotherapy effectivity | 5.987 [2.930-12.234] | P < 0.05 | 4.910 | 44.3% | P < 0.05 | 0.462 |
OR = odds ratio; CI = confidence interval.